NEW YORK, Aug. 10 – Invitrogen has exclusively licensed lentiviral gene-delivery technology from Cell Genesys for use in gene-expression research and drug-target validation, the companies said on Friday.
The agreement grants San Diego-based Invitrogen worldwide rights to sell kits, products, and services using the lentiviral-vector technology. In return, Invitrogen will pay Cell Genesys royalties on any sales, as well as a portion of fees generated from sublicensing the technology to companies applying the technology to commercial bioprocessing or in their own products.
Lentiviral gene delivery is one technique for modifying a cell or organism’s DNA by delivering genetic information directly into a cell’s nucleus. The method is particularly useful for gene expression and drug-target validation studies in non-dividing or slowly dividing cells, the companies said in a statement.
Cell Genesys, based in Foster City, Calif., is developing cancer vaccines and gene-therapy techniques for treating major diseases. For applications outside of this focus, the company is seeking partners to license its gene-delivery intellectual property.
Last week, Cell Genesys acquired Calydon, a Sunnyvale, Calif.-based biotechnology company focused on developing therapeutic products for cancer. Cell Genesys also holds a 10.5 percent stake in antibody manufacturer Abgenix, based in Fremont, Calif.